This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles
by Kaibalya Pravo Dey
The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.
Time to Buy Cigna (CI) or Humana's (HUM) Stock on News of a Potential Merger?
by Shaun Pruitt
News of a potential mega-merger between Cigna (CI) and Humana (HUM) made headlines in today's trading session and investors may be wondering if now is a good time to buy stock in these health giants.
Top Stock Reports for McDonald's, Amgen & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).
Here's Why Investors Should Hold Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) expects total medical customer growth to be a minimum of 1.4 million this year.
Why Cigna (CI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Stocks Set to Gain From Growing Membership, Tech Advancements
by Debasmita Chatterjee
Rising premiums, contract wins, a telehealth services suite and the M&A strategy are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from encouraging industry prospects.
Cigna (CI) Unit Unveils Pricing Model for Pharmacy Clients
by Zacks Equity Research
Cigna's (CI) sub-unit Express Scripts introduces a pricing option for prescription drugs that may bolster the customer base and fetch higher pharmacy revenues to the health insurer.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Why Cigna (CI) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna (CI) Q3 Earnings Beat on Membership Growth, '23 EPS View Up
by Zacks Equity Research
Cigna's (CI) Q3 results benefit on well-performing U.S. Commercial and Medicare Advantage businesses. Management currently expects 2023 adjusted EPS to be a minimum of $24.75.
Here's What Key Metrics Tell Us About Cigna (CI) Q3 Earnings
by Zacks Equity Research
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 1.65% and 2.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Cigna (CI) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Humana (HUM) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 8.81% and 0.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.
Cigna (CI) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $303.89, marking a -0.25% move from the previous day.
Molina (MOH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.70% and 2.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cigna (CI) Fell More Than Broader Market
by Zacks Equity Research
In the closing of the recent trading day, Cigna (CI) stood at $301.05, denoting a -1.87% change from the preceding trading day.
Here's Why Cigna (CI) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Cigna (CI) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, Cigna (CI) closed at $310.60, indicating a -0.49% shift from the previous trading day.
Q3 Earnings Scorecard and Analyst Reports for Walmart, Nike & TJX
by Sheraz Mian
Today's Research Daily features a real-time scorecard of the Q3 earnings season and new research reports on 16 stocks, including Walmart, Nike & TJX.